Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [615]

Choosing the right serum and molecular biomarkers in the Philippines

Dr Jose Jasper Andal - St Luke's Medical Center, Manila, Philippines

Choosing the right serum and molecular biomarkers in the Philippines ( Dr Jose Jasper Andal - St Luke's Medical Center, Manila, Philippines )

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR...

Prof Nicolas Girard - Institut Curie, Paris, France

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical...

Prof Nicolas Girard - Institut Curie, Paris, France

Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical benefit in patients with resectable NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

LUMINANCE: Results support use of durvalumab and platinum-etoposide for...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for...

Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1...

Dr Margarita Majem Tarruella - Hospital de la Santa Creu i Sant Pau, Barcelona...

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC ( Dr Margarita Majem Tarruella - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )

Neo-adjuvant therapy for different cancers in the Philippines

Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines

Neo-adjuvant therapy for different cancers in the Philippines ( Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines )

The role of curative neoadjuvant treatment in certain cancer types

Dr Arthur Gregory Lui - Metro Davao Medical Research Center, Davao del Sur...

The role of curative neoadjuvant treatment in certain cancer types ( Dr Arthur Gregory Lui - Metro Davao Medical Research Center, Davao del Sur, Philippines )

The pros and cons of breast IORT and ultra hypofractionation (FR)

Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France

$The pros and cons of breast IORT and ultra hypofractionation (FR) ( Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France )$

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG

Dr Roger Li - Moffitt Cancer Center, Tampa, USA

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )

More from ecancer